Identification of an intrinsic determinant critical for maspin subcellular localization and function

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Dzinic, Sijana H ^a,b   Kaplun, Alexander ^a,b,d   Li, Xiaohua ^a,b   Bernardo, Margarida ^a,b   Meng, Yonghong ^a,e   Dean, Ivory ^a,b   Krass, David ^a,b   Stemmer, Paul ^c   Shin, Namhee ^c   Lonardo, Fulvio ^a,c   Sheng, Shijie ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d BIOBASE Corporation   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID; HISTONE DEACETYLASE 1; LEPTOMYCIN B; MASPIN;

AMINO ACID SEQUENCE; ARTICLE; AVIADENOVIRUS; BINDING AFFINITY; CELL COMPARTMENTALIZATION; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; POINT MUTATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR GROWTH;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL NUCLEUS; ENDOPLASMIC RETICULUM; FATTY ACIDS, UNSATURATED; HISTONE DEACETYLASE 1; HISTONES; HUMANS; IMMUNOPRECIPITATION; MUTATION; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; SERPINS;

EID: 84896739400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074502     Document Type: Article

References (63)

1. Sheng SJ, Truong B, Fredrickson D, Wu RL, Pardee AB, et al. (1998) Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proceedings of the National Academy of Sciences of the United States of America 95: 499-504. (Pubitemid 28083771)
2. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, et al. (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemotherapy and Pharmacology 48: S20-S26. (Pubitemid 33738367)
3. Pemberton PA, Wong DT, Gibson HL, Kiefer MC, Fitzpatrick PA, et al. (1995) The Tumor-Suppressor Maspin Does Not Undergo the Stressed to Relaxed Transition or Inhibit Trypsin-Like Serine Proteases - Evidence That Maspin Is Not a Protease Inhibitory Serpin. Journal of Biological Chemistry 270: 15832-15837.
4. Al-Ayyoubi M, Gettins PGW, Volz K (2004) Crystal structure of human maspin, a serpin with antitumor properties - Reactive center loop of maspin is exposed but constrained. Journal of Biological Chemistry 279: 55540-55544. (Pubitemid 40066556)
5. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, et al. (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins - Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. Journal of Biological Chemistry 276: 33293-33296.
6. Biliran H Jr, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61: 8676-8682. (Pubitemid 34013876)
7. Li X, Yin S, Meng Y, Sakr W, Sheng S (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66: 9323-9329. (Pubitemid 44521155)
8. McGowen R, Biliran H Jr, Sager R, Sheng S (2000) The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 60: 4771-4778.
9. Lonardo F, Li X, Kaplun A, Soubani A, Sethi S, et al. (2010) The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr Pharm Des 16: 1877-1881.
10. Gao F, Shi HY, Daughty C, Cella N, Zhang M (2004) Maspin plays an essential role in early embryonic development. Development 131: 1479-1489. (Pubitemid 38559276)
11. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681. (Pubitemid 34619383)
12. Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, et al. (2011) Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer 2: 1009-1022.
13. Kaplun A, Dzinic S, Bernardo MM, Sheng SJ (2012) Tumor Suppressor Maspin as a Rheostat in HDAC Regulation to Achieve the Fine-Tuning of Epithelial Homeostasis. Critical Reviews in Eukaryotic Gene Expression 22: 249-258.
14. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, et al. (2002) Maspin is up-regulated in premalignant prostate epithelia. Prostate 53: 255-262. (Pubitemid 35398496)
15. Cher ML, Biliran HR, Bhagat S, Meng YH, Che MX, et al. (2003) Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 100: 7847-7852. (Pubitemid 36760058)
16. Zhang M, Magit D, Sager R (1997) Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci U S A 94: 5673-5678. (Pubitemid 27241828)
17. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, et al. (1994) Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529. (Pubitemid 24082753)
18. Xie L, Ying WT, Li BY, Zhang KT, Qian XH, et al. (2003) [Proteomics-based identification of Maspin differential expression in bronchial epithelial immortalized cells and malignant transformation cells]. Ai Zheng 22: 463-466.
19. Lonardo F, Li XH, Siddiq F, Singh R, At-Abbadi M, et al. (2006) Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51: 31-39. (Pubitemid 43088622)
20. Lockett J, Yin S, Li X, Meng Y, Sheng S (2006) Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem 97: 651-660.
21. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, et al. (2009) Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology 54: 590-597.
22. Mohsin SK, Zhang M, Clark GM, Craig Allred D (2003) Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199: 432-435. (Pubitemid 36411219)
23. Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, et al. (2006) Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101: 385-389. (Pubitemid 44251066)
24. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, et al. (2002) The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8: 2924-2932. (Pubitemid 35025740)
25. Goulet B, Chan G, Chambers AF, Lewis JD (2011) An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis (1) (1) This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journal's usual peer review process. Biochem Cell Biol.
26. Goulet B, Kennette W, Ablack A, Postenka CO, Hague N, et al. (2012) Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire 90: 109-109.
27. Bodenstine TM, Seftor REB, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, et al. (2012) Maspin: molecular mechanisms and therapeutic implications. Cancer and Metastasis Reviews 31: 529-551.
28. Feldherr CM, Akin D (1994) Role of Nuclear Trafficking in Regulating Cellular-Activity. International Review of Cytology - a Survey of Cell Biology, Vol 151 151: 183-228.
29. Law RH, Irving JA, Buckle AM, Ruzyla K, Buzza M, et al. (2005) The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix. Journal of Biological Chemistry 280: 22356-22364. (Pubitemid 40827892)
30. Ravenhill L, Wagstaff L, Edwards DR, Ellis V, Bass R (2010) G-helix of Maspin Mediates Effects on Cell Migration and Adhesion. Journal of Biological Chemistry 285: 36285-36292.
31. Sheng SJ, Pemberton PA, Sager R (1994) Production, Purification, and Characterization of Recombinant Maspin Proteins. Journal of Biological Chemistry 269: 30988-30993. (Pubitemid 24377588)
32. Zou ZQ, Anisowicz A, Hendrix MJC, Thor A, Neveu M, et al. (1994) Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial-Cells. Science 263: 526-529. (Pubitemid 24082753)
33. Kerppola TK (2006) Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nature Protocols 1: 1278-1286.
34. Yin SP, Li XH, Meng YH, Finley RL, Sakr W, et al. (2005) Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. Journal of Biological Chemistry 280: 34985-34996. (Pubitemid 41504634)
35. Al-Ayyoubi M, Gettins PG, Volz K (2004) Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. J Biol Chem 279: 55540-55544. (Pubitemid 40066556)
36. Grebenok RJ, Pierson E, Lambert GM, Gong FC, Afonso CL, et al. (1997) Green-fluorescent protein fusions for efficient characterization of nuclear targeting. Plant J 11: 573-586. (Pubitemid 27158962)
37. Ogawa H, Inouye S, Tsuji FI, Yasuda K, Umesono K (1995) Localization, trafficking, and temperature-dependence of the Aequorea green fluorescent protein in cultured vertebrate cells. Proc Natl Acad Sci U S A 92: 11899-11903. (Pubitemid 26014217)
38. Morin X, Daneman R, Zavortink M, Chia W (2001) A protein trap strategy to detect GFP-tagged proteins expressed from their endogenous loci in Drosophila. Proceedings of the National Academy of Sciences of the United States of America 98: 15050-15055. (Pubitemid 34013967)
39. Wolff B, Sanglier JJ, Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chemistry & Biology 4: 139-147. (Pubitemid 27161752)
40. OssarehNazari B, Bachelerie F, Dargemont C (1997) Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 278: 141-144.
41. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, et al. (1994) Leptomycin-B Targets a Regulatory Cascade of Crm1, a Fission Yeast Nuclear-Protein, Involved in Control of Higher-Order Chromosome Structure and Gene-Expression. Journal of Biological Chemistry 269: 6320-6324. (Pubitemid 24191000)
42. Kim JY, Shen S, Dietz K, He Y, Howell O, et al. (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nature Neuroscience 13: 180-U163.
43. Pelham HRB (1988) Evidence That Luminal Er Proteins Are Sorted from Secreted Proteins in a Post-Er Compartment. Embo Journal 7: 913-918.
44. Munro S, Pelham HRB (1987) A C-Terminal Signal Prevents Secretion of Luminal Er Proteins. Cell 48: 899-907.
45. Teoh SSY, Whisstock JC, Bird PI (2010) Maspin (SERPINB5) Is an Obligate Intracellular Serpin. Journal of Biological Chemistry 285: 10862-10869.
46. Endsley MP, Hu Y, Deng Y, He X, Warejcka DJ, et al. (2011) Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion. J Biol Chem 286: 24599-24607.
47. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, et al. (2003) Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. Journal of Biological Chemistry 278: 7607-7616. (Pubitemid 36800769)
48. Delpino A, Piselli P, Vismara D, Vendetti S, Colizzi V (1998) Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin. Molecular Membrane Biology 15: 21-26. (Pubitemid 28182080)
49. Ni M, Zhou H, Wey SA, Baumeister P, Lee AS (2009) Regulation of PERK Signaling and Leukemic Cell Survival by a Novel Cytosolic Isoform of the UPR Regulator GRP78/BiP. Plos One 4.
50. Belfi CA, Chatterjee S, Gosky DM, Berger SJ, Berger NA (1999) Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. Biochemical and Biophysical Research Communications 257: 361-368. (Pubitemid 29301450)
51. Hu CD, Chinenov Y, Kerppola TK (2002) Visualization of interactions among bZip and Rel family proteins in living cells using bimolecular fluorescence complementation. Molecular Cell 9: 789-798. (Pubitemid 34454889)
52. Song Y, Shiota M, Tamiya S, Kuroiwa K, Naito S, et al. (2011) The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology 58: 773-780.
53. Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, et al. (2008) MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leukemia Research 32: 1382-1392.
54. Kato T, Shimono Y, Hasegawa M, Jijiwa M, Enomoto A, et al. (2009) Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress. Cancer Research 69: 3597-3604.
55. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193. (Pubitemid 29436325)
56. Min J, Landry J, Sternglanz R, Xu RM (2001) Crystal structure of a SIR2 homolog-NAD complex. Cell 105: 269-279. (Pubitemid 32429516)
57. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12: 1325-1334. (Pubitemid 38900774)
58. Lee SJ, Jang H, Park C (2012) Maspin increases Ku70 acetylation and Bax-mediated cell death in cancer. Int J Mol Med 29: 225-230.
59. Li X, Kaplun A, Lonardo F, Heath E, Sarkar FH, et al. (2011) HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Mol Cancer Res 9: 733-745.
60. Jang HL, Nam E, Lee KH, Yeom S, Son HJ, et al. (2008) Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. International Journal of Molecular Medicine 22: 333-338.
61. Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551.
62. Balasubramanian S, Verner E, Buggy JJ (2009) Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280: 211-221.
63. Delcuve GP, Khan DH, Davie JR (2013) Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets 17: 29-41.